On the other hand, our data indicate that blockade of peripheral CB1R (mainly in the liver), independent of weight loss, is sufficient to ameliorate obesity-induced hepatic steatosis and liver injury, insulin resistance, and hypertriglyceridemia; these effects are known to be mediated via blocking the CB1R in hepatocytes [10,26,27,32,39,[75], [76], [77], [78], [79]]. The gene discussed is CNR1; the disease is fatty liver disease.